Patient #7 developed anaplastic lymphoma kinase‐negative anaplastic large cell lymphoma (ALCL) after achieving CR with mogamulizumab plus EPOCH therapy for aggressive ATLL. Here, ALK is linked to anaplastic large cell lymphoma.